Greetings,
The FDA Oncology Center of Excellence (OCE) will be presenting a public panel discussion, “More Isn’t Always Better: Understanding Cancer Treatment Tolerability” on Thursday, March 10, 2022 at 2PM ET.
The key topic will be understanding tolerability with regard to current cancer treatments. Patients, clinicians, researchers, and FDA representatives will be sharing their unique perspectives.
The speakers will discuss the importance and integration of the patient experience in evaluating tolerability, clinician consideration of patient-reported tolerability, the impact of tolerability on treatment decisions, and dose optimization.
Registration for this event is complimentary and open to the public: surveymonkey.com/r/03102022
Featured Speakers:
•Ethan Basch, MD, MSc, Richard M. Goldberg Distinguished Professor in Medical Oncology | Professor of Public Health, Health Policy and Management, Gillings School of Global Public Health
•Jill Feldman, Patient Advocate | Co-Founder of EGFR Resisters
•Erica Horodniceanu, MPH, Health Scientist, Patient Focused Drug Development | Oncology Center of Excellence, FDA
•Lee Jones, Colon Cancer Survivor | Patient Advocate
•Anne Loeser, Patient Advocate, Author of the Insider's Guide to Metastatic Breast Cancer, Founder - Patient-Centered Dosing Initiative , Individual Member - Metastatic Breast Cancer Alliance
•Dr. Richard Pazdur, MD, Director, Oncology Center of Excellence, FDA
•Dr. Mirat Shah, MD, Medical Oncologist and Clinical Reviewer | Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA
•Moderator: Rea Blakey, Associate Director for External Outreach and Engagement, Oncology Center of Excellence, FDA
Hope to see you there!
What question do you have for metastatic expert Dr. Nancy Lin \"Ask Me Anything\"?
Recent and upcoming surgery
Free Upcoming Radical Remission Docuseries
